Our results showed fluctuating PIP 2 levels, which were inversely related to the amount of PI-PLCb-1 and directly related to the levels of activated Akt, indicating a possible correlation between these two molecules. In fact, as Figure 2 shows, when the patient displayed high-levels of activated Akt, for example before the beginning of the treatment, he demonstrated low-levels of PI-PLCb-1. On the contrary, when the expression of PI-PLCb-1 reached its highest level, that corresponded to the lowest levels of activated Akt. These molecular findings, together with the clinical data of the patient, are consistent with the hypothesis that in high-risk MDS cases azacitidine might have a direct effect on PI-PLCb-1, which could play an essential role in MDS, as well as activated Akt, whose pathways are correlated to the imbalance of the apoptotic processes in MDS cells. Moreover, it is reasonable to hypothesize that the balance between these two molecules could be directly related to PIP 2 levels.
Acute promyelocytic leukemia (APL) represents about 10% of acute myeloid leukemias and is characterized by a specific translocation between chromosomes 15 and 17, resulting in the fusion of the putative transcription factor promyelocytic leukemia gene (PML) to the retinoic acid receptor a gene (RARA). 1 This fusion PML-RARA protein blocks differentiation at the promyelocytic stage and is uniquely sensitive to all-trans retinoic acid and arsenic trioxide with significantly improved outcome of APL patients. However, complete remission is not always durable and relapse is often associated with resistance. 2 Breakpoints in the PML gene in APL are grouped in three cluster regions (bcr1-3) with fusion to a single breakpoint region in the RARA gene. The common breakpoints in APL are bcr1, referring to breakpoint within PML intron 6 and bcr3, with breakpoint in PML intron 3. As the PML gene consists of nine exons, from which exons 4-6 may be skipped, in the bcr1-type Letters to the Editor APL several spliced transcripts are generated. 2, 3 It was suggested that the different PML splice variants could add new functional domains to the protein. 2 In APL, similar splicing occurs in the PML portion within the PML-RARA fusion molecule. Several sets of primers have been defined that allow the amplification of PML-RARA transcripts. Using a nested reverse transcriptase-PCR (RT-PCR) approach, the different isoforms are amplified, generating several transcripts, among which is an isoform lacking PML exon 5. The PML protein consists of an N-terminal proline-rich motif, a cysteine-rich motif, an a-helical domain, a leucine zipper homologous region and a serine-rich motif. 2 The absence of exon 5, part of the a-helical domain, was suggested to result in all-trans retinoic acid resistance. 4 In this study, 34 adult APL patients diagnosed positive for PML-RARA fusion were analyzed by fluorescence in situ hybridization (FISH) and nested RT-PCR. All bcr1-type APL patients exhibited at diagnosis three PML-RARA isoforms involving different splice variants of PML joined to RARA exon 3 ( Figures 1a and b, lane 3) . Two of these PML splice variants are in frame, one consisting of PML exons 3-6 (long isoform, 829 bp product) and the second with exons 3, 4 and 6 lacking exon 5 (short isoform, 625 bp product). The third PML isoform is out of frame consisting of PML exons 3 and 4 and skipping exons 5 and 6 (426 bp product). In all of these cases, expressing the three PML isoforms, both at diagnosis and disease relapse, FISH results were always positive. Twenty-five patients under treatment were found to be negative by both nested RT-PCR and FISH techniques and remained negative for a long-term followup (representative samples in Figure 1b , lanes 4, 6 and 7). However, in nine patients during routine periodical analyses under treatment, discrepancies between positive RT-PCR results and FISH negativity were observed ( Figure 2 ). This discrepancy appeared during two time periods, in patients analyzed a short time after the initiation of therapy ( Figure 2 ; patients 1-5) and months later while still under therapy ( Figure 2 ; patients 5-9). In all of these cases, at points in which FISH was negative and RT-PCR was positive, the only isoform detected was the short PML-RARA isoform (representative samples in Figure 1b , lanes 5 and 8). The presence of this short PML-RARA isoform, skipping exon 5, was confirmed by direct sequencing in all of these cases (representative sequence in Figure 1c ).
In particular, while FISH was negative, patients 1-4 exhibited the short PML isoform up to 2 months from initiation of treatment and then became negative by both RT-PCR and FISH and have remained negative up to date. Patients 5-9 were subject to disease relapses, four of whom deceased a short time after disease relapse. Patient number 5 exhibited the short isoform both shortly after initiation of treatment and 10 months from diagnosis, a short time after molecular relapse (2.8% FISHpositive). Treatment was changed to arsenic acid and the patient died a short period afterward from disease relapse (100% FISHpositive for PML-RARA). Patient number 6 was analyzed only 6 months after diagnosis and initiation of therapy when he was negative by both RT-PCR and FISH. At 18 months from treatment initiation, molecular relapse was observed (FISHpositive for PML-RARA in 2% of cells); at this point, treatment was changed to arsenic acid. A few months later, while FISH results were negative, the short isoform was detected and within a short period of time this patient underwent a second relapse (5% of cells PML-RARA-positive by FISH) and died. Patient number 7 was analyzed only a year after diagnosis and was negative by both RT-PCR and FISH for PML-RARA. A few weeks later, FISH remained negative but RT-PCR was positive for the short isoform. Twenty-six months later, this patient had disease relapse (89% FISH-positive) and died shortly afterward. Samples from patient number 8 were negative by FISH and RT-PCR for up to 31 months from diagnosis. A few months later, this patient relapsed (37.5% of cells positive by FISH). Before and after relapse, the patient was FISH-negative but expressed the short isoform. Treatment was changed to arsenic and the patient became negative by both FISH and RT-PCR for a long period of time. A second relapse was developed 56 months after diagnosis (5-90% FISH-positive cells). However, within a short period, the short isoform was detected again and the patient underwent Figure 1 (a) Illustration of the PML-RARA isoforms. Upper: an isoform of PML with exons 3-6 joined to exon 3 of RARA. Middle: a short isoform of PML lacking exon 5. Lower: an out-of-frame isoform lacking exons 5 and 6. Bottom: three different primer sets commonly used for the detection of PML-RARA fusion. Set IFa nested PCR designed from exon 3 that detects all possible PML-RARA isoforms as different bands. 5 Set IIFa nested PCR designed from exon 5, not detecting the short isoform. 6 Set IIIFa nested PCR designed from exon 6, detecting all PML-RARA isoforms as a single band. . PML isoform consisting of exon 4, skipping exon 5 and followed by exon 6 fused to RARA exon 3. PCR products were sequenced on an 3100h ABI sequencer using Big Dye terminator system (Applied Biosystems, Foster City, CA, USA).
Letters to the Editor auto-stem cell transplantation (SCT) and died shortly afterward. Patient number 9 relapsed several times within a period of 97 months. Between relapses, the short isoform was detected three times in bone marrow (BM) samples. Interestingly, peripheral blood (PB) obtained from the same dates was completely negative by both methods (data not shown). This coincided with the fact that BM sample is more accurate and sensitive than PB sample. After the second relapse, the treatment was changed to arsenic and after the third relapse the patient underwent auto-SCT. The short isoform reappeared again 82 months after diagnosis. From that period up till now, this patient remained negative by both methods.
APL is characterized by a reciprocal translocation t(15:17) resulting in chimeric PML-RARA and RARA-PML fusions. The existence of different breakpoint regions in the PML and the presence of alternative splicing of PML transcripts are responsible for the great heterogeneity of PML-RARA junctions. Among the known PML alternative spliced transcripts, several isoforms skipping exon 5 have been described. 2 Numerous sets of primers have been developed in order to detect all types of PML-RARA junctions in all APL patients. In general, three different approaches of nested RT-PCR for PML-RARA detection exist. All three techniques use forward primers from PML exon 3 and reverse primers from RARA exon 3 for the first round of PCR. By contrast, each approach differs in its nested PCR PML primers' design. The first set, routinely used in our laboratory, utilizes primers from exon 3 (bottom of Figure 1a Figure 1a , depicted as set II (ref. 6) uses primers from exon 5 for the nested PCR. Using this approach, PML-RARA will be detected as a single-band product and other PML isoforms will not be detected, including the one skipping exon 5. The third set (bottom of Figure 1a, set III (ref. 7) ) uses nested primers from PML exon 6, resulting in a single product for all possible PML isoforms. The comparison between the three methods, commonly used for PML-RARA detection, shows that primer sets I and III (refs. 5 and 7) can detect the short isoform skipping exon 5; however, while set I can differentiate between dissimilar positive result (e.g., three PML-RARA products and a single 685 bp product), using the third set will result in the same band size for all isoforms. In contrast, set II primers 6 will not at all be able to detect the PML isoform lacking exon 5 and will provide a false-negative result. We can conclude that in order to identify all possible PML-RARA splice variants, a nested PCR should be performed from PML exon 3 or 6. Moreover, the only set that can differentiate between the situation in which only the short isoform is present is set I designed by Borrow et al. 5 Although, in general, there is a complete agreement between PCR and FISH results at diagnosis and relapse of APL, even at a very low percentage of FISH-positive cells, there are points at which FISH is defined negative while PCR result is positive. It is 2% (mean73 s.d.) . FISH was performed on at least 400 interphase nuclei of the patient samples, according to our standard FISH protocol by two independent observers. 8 Under remission, when minimal residual disease was analyzed, up to 1000 interphase nuclei were analyzed.
Letters to the Editor particularly interesting to note that in this situation the PCR always results in a single band of the 685bp, representing the expression of the isoform lacking exon 5. This indicates that a small number of cells, below the FISH detection level, are exclusively expressing the short isoform. This single-isoform expression observed in this work was reported previously by Takatsuki et al., 4 who examined the expression of PML/RAR-a in hematopoietic colonies in five APL patients by RT-PCR analysis. They described three different types of colonies: those expressing only the 780 bp fragment (equivalent to the long isoform), those expressing only the 640 bp fragment (equivalent to the short isoform) and those expressing both fragments, suggesting that alternative splicing was clonally determined in each colony. In addition, our data showed that the isoform lacking exon 5 disappeared last during treatment (Figure 2 , patients 1-5) and appeared around relapse periods (Figure 2, patients 5-9 ). This suggests that the clones expressing the long isoform had responded to therapy and that their numbers had decreased, while cells expressing the PML-RARA isoform lacking exon 5 are more resistant to therapy and therefore remain detectable. As exon 5 is part of the a-helical domain, it was suggested previously that its absence may influence response to treatment. 4 Moreover, the fact that a small number of cells possess a high level of expression of a specific isoform suggests that this isoform is of an aggressive nature.
To conclude, in this work we utilized nested RT-PCR to monitor the different PML-RARA fusion isoforms and discovered that an isoform lacking exon 5 can be differentiated from other positive results using set I primers as designed by Borrow et al. 5 We suggest that clinical laboratories analyzing PML-RARA patients may benefit from identifying the different isoforms, giving additional information to the clinicians. We have shown that this transcript disappears last under therapy initiation and reappears first around relapse periods, suggesting the persistence of such a transcript. Many types of cancers are currently treated with high-dose chemotherapy, which affects all (rapidly) dividing cells, including hematopoietic progenitor cells (HPCs). Therefore, even after stem cell transplantation, patients often suffer from a period of pancytopenia. Anemia and leukopenia, in this respect, can be successfully treated with Epo and G-CSF, respectively, by inducing a faster recovery of hemoglobin and neutrophil levels. Several attempts have been undertaken to shorten the period of thrombocytopenia by co-transplantation of autologous megakaryocytes (MKs) expanded from CD34 þ HPCs, but the effect of this treatment was variable and if present, minimal.
1-4 However, the MK expansion protocols used in these clinical trials vary considerably and optimization of the composition of the transplant may therefore increase the clinical benefit of co-transplantation of expanded MKs. We therefore investigated whether MKs generated from mobilized peripheral blood (MPB) CD34 þ could induce fast platelet production when combined with unmanipulated CD34 þ cells after transplantation in the nonobese diabetic/severe combined immunodeficiency (NOD/ SCID) mouse. For this purpose, CD34 þ cells were cultured for 7 days with 100 ng ml À1 thrombopoietin (Tpo) and 10 ng ml interleukin-1b (IL-1b), a cytokine cocktail, previously shown to efficiently generate MK progenitors and mature MKs (up to 32N) in our lab. 5 The NOD/SCID mouse model has long been accepted as a model for human hematopoiesis. 6 Transplantation of human MPB CD34
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